About

A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.

Discovery of precision degrader antibody conjugates (pDACs) employing novel SMARCA2/4 degrader payloads

Andrew W. Buesking, Sr. Director, Chemistry on behalf of the pDAC team